TLDR Clascoterone safely promotes hair growth similar to minoxidil.
The document titled "A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia" from October 2019 summarizes the findings from in vitro and clinical trials of clascoterone, a topical androgen receptor antagonist being investigated for the treatment of androgenetic alopecia. The studies found that clascoterone is well-tolerated, has minimal systemic exposure, and demonstrated a notable hair growth signal comparable to minoxidil. The combination of research and publications, strong letters of recommendation, dermatology rotations, high USMLE scores, and a reputable postgraduate training were found to give international applicants the highest chance of matching to dermatology residency in the US. A survey-based comparison of sun safety practices found that those who seek skin cancer screenings are more likely to practice proper photoprotective practices than a randomly sampled population.View this study on jaad.org →